176 related articles for article (PubMed ID: 30778049)
1. PD-1-siRNA delivered by attenuated Salmonella enhances the antimelanoma effect of pimozide.
Zhao T; Wei T; Guo J; Wang Y; Shi X; Guo S; Jia X; Jia H; Feng Z
Cell Death Dis; 2019 Feb; 10(3):164. PubMed ID: 30778049
[TBL] [Abstract][Full Text] [Related]
2. Antitumor effects and mechanisms of CpG ODN combined with attenuated Salmonella-delivered siRNAs against PD-1.
Jia X; Guo J; Guo S; Zhao T; Liu X; Cheng C; Wang L; Zhang B; Meng C; Jia H; Luo E
Int Immunopharmacol; 2021 Jan; 90():107052. PubMed ID: 33310296
[TBL] [Abstract][Full Text] [Related]
3. Plasmid co-expressing siRNA-PD-1 and Endostatin carried by attenuated Salmonella enhanced the anti-melanoma effect via inhibiting the expression of PD-1 and VEGF on tumor-bearing mice.
Wei T; Li Y; Li B; Xie Q; Huang Y; Wu Z; Chen H; Meng Y; Liang L; Wang M; Geng J; Lei M; Shang J; Guo S; Yang Z; Jia H; Ren F; Zhao T
Int Immunopharmacol; 2024 Jan; 127():111362. PubMed ID: 38103411
[TBL] [Abstract][Full Text] [Related]
4. The enhanced antitumour response of pimozide combined with the IDO inhibitor L‑MT in melanoma.
Jia H; Ren W; Feng Y; Wei T; Guo M; Guo J; Zhao J; Song X; Wang M; Zhao T; Wang H; Feng Z; Tian Z
Int J Oncol; 2018 Sep; 53(3):949-960. PubMed ID: 30015838
[TBL] [Abstract][Full Text] [Related]
5. A self-designed CpG ODN enhanced the anti-melanoma effect of pimozide.
Jia H; Guo J; Wang P; Sun K; Chen J; Ren W; Wei T; Yang Y; Li J; Liu X; Li R; Zhong J; Wang M; Tian Z; Feng Z; Zhao T
Int Immunopharmacol; 2020 Jun; 83():106397. PubMed ID: 32220805
[TBL] [Abstract][Full Text] [Related]
6. PD-1-siRNA Delivered by Attenuated
Lu S; Gao J; Jia H; Li Y; Duan Y; Song F; Liu Z; Ma S; Wang M; Zhao T; Zhong J
Front Immunol; 2021; 12():707991. PubMed ID: 34295341
[TBL] [Abstract][Full Text] [Related]
7. Combination of attenuated Salmonella carrying PD-1 siRNA with nifuroxazide for colon cancer therapy.
Zhao T; Feng Y; Guo M; Zhang C; Wu Q; Chen J; Guo S; Liu S; Zhou Q; Wang Z; Fan W; Zhang Y; Jia H; Feng Z
J Cell Biochem; 2020 Feb; 121(2):1973-1985. PubMed ID: 31692041
[TBL] [Abstract][Full Text] [Related]
8. RNA interference targeting programmed death receptor-1 improves immune functions of tumor-specific T cells.
Borkner L; Kaiser A; van de Kasteele W; Andreesen R; Mackensen A; Haanen JB; Schumacher TN; Blank C
Cancer Immunol Immunother; 2010 Aug; 59(8):1173-83. PubMed ID: 20349059
[TBL] [Abstract][Full Text] [Related]
9. Checkpoint blockade immunotherapy enhances the frequency and effector function of murine tumor-infiltrating T cells but does not alter TCRβ diversity.
Kuehm LM; Wolf K; Zahour J; DiPaolo RJ; Teague RM
Cancer Immunol Immunother; 2019 Jul; 68(7):1095-1106. PubMed ID: 31104075
[TBL] [Abstract][Full Text] [Related]
10. Silencing of STAT3 via Peptidomimetic LNP-Mediated Systemic Delivery of RNAi Downregulates PD-L1 and Inhibits Melanoma Growth.
Ehexige E; Bao M; Bazarjav P; Yu X; Xiao H; Han S; Baigude H
Biomolecules; 2020 Feb; 10(2):. PubMed ID: 32059541
[TBL] [Abstract][Full Text] [Related]
11. TLR7 agonist in combination with Salmonella as an effective antimelanoma immunotherapy.
Vola M; Mónaco A; Bascuas T; Rimsky G; Agorio CI; Chabalgoity JA; Moreno M
Immunotherapy; 2018 Jun; 10(8):665-679. PubMed ID: 29562809
[TBL] [Abstract][Full Text] [Related]
12. The combination of chemotherapy with HVJ-E containing Rad51 siRNA elicited diverse anti-tumor effects and synergistically suppressed melanoma.
Kiyohara E; Tamai K; Katayama I; Kaneda Y
Gene Ther; 2012 Jul; 19(7):734-41. PubMed ID: 21900962
[TBL] [Abstract][Full Text] [Related]
13. SCIB1, a huIgG1 antibody DNA vaccination, combined with PD-1 blockade induced efficient therapy of poorly immunogenic tumors.
Xue W; Brentville VA; Symonds P; Cook KW; Yagita H; Metheringham RL; Durrant LG
Oncotarget; 2016 Dec; 7(50):83088-83100. PubMed ID: 27825115
[TBL] [Abstract][Full Text] [Related]
14. Targeted siRNA silencing of indoleamine 2, 3-dioxygenase in antigen-presenting cells using mannose-conjugated liposomes: a novel strategy for treatment of melanoma.
Chen D; Koropatnick J; Jiang N; Zheng X; Zhang X; Wang H; Yuan K; Siu KS; Shunnar A; Way C; Min WP
J Immunother; 2014; 37(2):123-34. PubMed ID: 24509175
[TBL] [Abstract][Full Text] [Related]
15. DNA and adenovirus tumor vaccine expressing truncated survivin generates specific immune responses and anti-tumor effects in a murine melanoma model.
Zhang H; Wang Y; Liu C; Zhang L; Xia Q; Zhang Y; Wu J; Jiang C; Chen Y; Wu Y; Zha X; Yu X; Kong W
Cancer Immunol Immunother; 2012 Oct; 61(10):1857-67. PubMed ID: 22706381
[TBL] [Abstract][Full Text] [Related]
16. Enhanced antitumor immune response in melanoma tumor model by anti-PD-1 small interference RNA encapsulated in nanoliposomes.
Barati M; Mirzavi F; Nikpoor AR; Sankian M; Namdar Ahmadabad H; Soleimani A; Mashreghi M; Tavakol Afshar J; Mohammadi M; Jaafari MR
Cancer Gene Ther; 2022 Jun; 29(6):814-824. PubMed ID: 34341501
[TBL] [Abstract][Full Text] [Related]
17. Exploiting in situ antigen generation and immune modulation to enhance chemotherapy response in advanced melanoma: A combination nanomedicine approach.
Lu Y; Wang Y; Miao L; Haynes M; Xiang G; Huang L
Cancer Lett; 2016 Aug; 379(1):32-8. PubMed ID: 27235608
[TBL] [Abstract][Full Text] [Related]
18. Beyond melanoma: inhibiting the PD-1/PD-L1 pathway in solid tumors.
Gentzler R; Hall R; Kunk PR; Gaughan E; Dillon P; Slingluff CL; Rahma OE
Immunotherapy; 2016 May; 8(5):583-600. PubMed ID: 27140411
[TBL] [Abstract][Full Text] [Related]
19. The siRNA-mediated downregulation of PD-1 alone or simultaneously with CTLA-4 shows enhanced in vitro CAR-T-cell functionality for further clinical development towards the potential use in immunotherapy of melanoma.
Simon B; Harrer DC; Schuler-Thurner B; Schaft N; Schuler G; Dörrie J; Uslu U
Exp Dermatol; 2018 Jul; 27(7):769-778. PubMed ID: 29704887
[TBL] [Abstract][Full Text] [Related]
20. Phosphatidylserine-targeting antibodies augment the anti-tumorigenic activity of anti-PD-1 therapy by enhancing immune activation and downregulating pro-oncogenic factors induced by T-cell checkpoint inhibition in murine triple-negative breast cancers.
Gray MJ; Gong J; Hatch MM; Nguyen V; Hughes CC; Hutchins JT; Freimark BD
Breast Cancer Res; 2016 May; 18(1):50. PubMed ID: 27169467
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
